Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress

We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is among the best pharmaceutical stocks.

TheFly reported on May 7 that AMLX reported first-quarter 2026 results for the period ended March 31, 2026, alongside pipeline and clinical updates. R&D expenses rose to $27.6 million from $22.1 million a year earlier, driven mainly by increased spending on avexitide development for post-bariatric hypoglycemia and milestone payments tied to the AMX0318 program. SG&A expenses increased slightly to $16.2 million from $15.7 million due to higher professional and consulting costs. Net loss widened to $41.3 million, or $0.37 per share, compared with $35.9 million, or $0.42 per share, in the prior-year period. The company ended the quarter with $279.8 million in cash, cash equivalents, and short-term investments, supporting operations into 2028.

Moreover, earlier on May 5, Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced the initiation of a U.S. Expanded Access Program allowing treatment access to avexitide for up to 250 adults with post-bariatric hypoglycemia. The program provides physicians the ability to request the investigational glucagon-like peptide-1 receptor antagonist for patients with significant unmet medical needs who cannot join ongoing clinical trials and have limited remaining treatment options.

Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress

Eligibility includes individuals with PBH following Roux-en-Y gastric bypass surgery, including those who have completed the Phase 3 LUCIDITY trial or previously participated in related studies. The program is designed to expand controlled access to avexitide under defined clinical criteria while broader development continues for the therapy in PBH.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative and endocrine diseases with high unmet medical needs.

While we acknowledge the risk and potential of AMLX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMLX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1